Viking Therapeutics, Inc - VKTX STOCK NEWS

Viking Therapeutics (NASDAQ: VKTX) announced their participation in two investor conferences: the 34th Annual Roth Conference from March 13-15, 2022, and the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. CEO Brian Lian will engage in a fireside chat and management will hold one-on-one meetings at Roth. At Oppenheimer, Lian will present on March 16 at 11:40 a.m. Pacific. The Oppenheimer presentation will be available via webcast. Viking focuses on developing therapies for metabolic disorders, including VK2809 for NASH and fibrosis.

Viking Therapeutics (NASDAQ: VKTX) announced its Q4 and full-year 2021 financial results, reporting a net loss of $12.4 million, or $0.16 per share, and a total net loss of $55.0 million, or $0.71 per share, for the year. The company continues its Phase 2b VOYAGE trial for VK2809, targeting NASH, while facing a clinical hold on the VK0214 trial for X-ALD pending additional studies. Viking maintains a strong cash position with over $200 million to support its clinical programs. New pipeline developments include VK2735, a dual GLP-1 and GIP receptor agonist.

Viking Therapeutics (NASDAQ: VKTX) announced its CEO, Brian Lian, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The chat is scheduled for February 16 at 2:00 PM Pacific. Attendees can access the live webcast via Viking's website in the Investors & Media section. Viking focuses on developing novel therapies for metabolic and endocrine disorders, including its lead candidate VK2809 for treating NASH.

Viking Therapeutics (NASDAQ: VKTX) will release its financial results for Q4 and year-end 2021 on February 9, 2022, after market close. The company will also host a conference call at 4:30 PM ET to discuss these results, along with general corporate updates. Investors can participate via phone or listen to the live webcast on Viking's website. Viking is focused on developing therapies for metabolic disorders, with candidates like VK2809, VK0214, and VK2735 in various stages of clinical trials.

Viking Therapeutics, Inc. (VKTX) announced a clinical hold by the FDA on its Phase 1b trial of VK0214 for X-linked adrenoleukodystrophy (X-ALD). The FDA requires an additional preclinical study, specifically a rodent genotoxicity study, before the trial can continue. This hold is not based on any findings from prior studies. The company expects to submit the requested data in Q2 2022, aiming to resume dosing later this year. VK0214 has previously shown promising safety and efficacy results, including reductions in LDL cholesterol and triglycerides.

Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial for VK2735, a novel dual agonist targeting GLP-1 and GIP receptors, aimed at treating metabolic disorders. This double-blind, placebo-controlled study will assess safety, tolerability, and pharmacokinetics in healthy adults, with exploratory assessments of body weight and liver fat changes. VK2735 is expected to enhance therapeutic effects compared to existing treatments like semaglutide. The trial marks a significant milestone for Viking, which aims to report topline results later in the year.

Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.

Viking Therapeutics (NASDAQ: VKTX) will present at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Brian Lian, Ph.D., is scheduled to speak on November 16 from 4:00 to 4:30 p.m. Eastern. Interested parties can access the presentation via the company's website, with a replay available post-conference. Viking focuses on therapies for metabolic and endocrine disorders, including VK2809, currently in a Phase 2b study for non-alcoholic steatohepatitis.

Viking Therapeutics (VKTX) reported its Q3 2021 financial results with a net loss of $13.2 million ($0.17 per share), compared to a loss of $9.3 million ($0.13 per share) in Q3 2020. The increase in loss was attributed to rising research and development expenses, now totaling $10.8 million, primarily for clinical studies. Viking is advancing its clinical pipeline, including ongoing Phase 2b VOYAGE trial for VK2809 in NASH and Phase 1b trial for VK0214 in X-ALD. The company ended Q3 with $216 million in cash, positioning it well for future developments.